Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment and prognosis of cerebral venous thrombosis

José M Ferro, MD, PhD
Patrícia Canhão, MD, PhD
Section Editor
Scott E Kasner, MD
Deputy Editor
John F Dashe, MD, PhD


Cerebral venous thrombosis (CVT) is an uncommon but serious disorder. Clinical manifestations can include headache, papilledema, visual loss, focal or generalized seizures, focal neurologic deficits, confusion, altered consciousness, and coma.

Many cases have been linked to inherited and acquired thrombophilias, pregnancy, puerperium, infection, and malignancy. Infarctions due to CVT are often hemorrhagic and associated with vasogenic edema. (See "Etiology, clinical features, and diagnosis of cerebral venous thrombosis".)

Treatment, which is started as soon as the diagnosis is confirmed, consists of reversing the underlying cause when known, control of seizures and intracranial hypertension, and antithrombotic therapy. Anticoagulation is the mainstay of acute and subacute treatment for CVT.

This topic will review the prognosis and treatment of CVT. Other aspects of this disorder are discussed separately. (See "Etiology, clinical features, and diagnosis of cerebral venous thrombosis".)


Cerebral venous thrombosis (CVT) can result in death or permanent disability, but usually has a favorable prognosis.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jan 2016. | This topic last updated: May 5, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Canhão P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005; 36:1720.
  2. Borhani Haghighi A, Edgell RC, Cruz-Flores S, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012; 43:262.
  3. Kenet G, Kirkham F, Niederstadt T, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol 2007; 6:595.
  4. Diaz JM, Schiffman JS, Urban ES, Maccario M. Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand 1992; 86:390.
  5. Crassard I, Canhão P, Ferro JM, et al. Neurological worsening in the acute phase of cerebral venous thrombosis in ISCVT (International Study on Cerebral Venous Thrombosis). Cerebrovasc Dis 2003; 16 Supp 4:60.
  6. Ferro JM, Canhão P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664.
  7. Rondepierre P, Hamon M, Leys D, et al. [Cerebral venous thromboses: study of the course]. Rev Neurol (Paris) 1995; 151:100.
  8. Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke 1996; 27:243.
  9. de Bruijn SF, de Haan RJ, Stam J. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group. J Neurol Neurosurg Psychiatry 2001; 70:105.
  10. Ferro JM, Lopes MG, Rosas MJ, et al. Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study. Cerebrovasc Dis 2002; 13:272.
  11. Breteau G, Mounier-Vehier F, Godefroy O, et al. Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol 2003; 250:29.
  12. Cakmak S, Derex L, Berruyer M, et al. Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors. Neurology 2003; 60:1175.
  13. Ferro JM, Canhão P, Crassard I, et al. External validation of a prognostic model of cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2005; 19 Suppl 2:154.
  14. Coutinho JM, Ferro JM, Canhão P, et al. Cerebral venous and sinus thrombosis in women. Stroke 2009; 40:2356.
  15. Girot M, Ferro JM, Canhão P, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke 2007; 38:337.
  16. Ferro JM, Canhão P, Stam J, et al. Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome. Stroke 2009; 40:3133.
  17. Baumgartner RW, Studer A, Arnold M, Georgiadis D. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiatry 2003; 74:459.
  18. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood 2006; 108:1129.
  19. Strupp M, Covi M, Seelos K, et al. Cerebral venous thrombosis: correlation between recanalization and clinical outcome--a long-term follow-up of 40 patients. J Neurol 2002; 249:1123.
  20. Martinelli I, Bucciarelli P, Passamonti SM, et al. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121:2740.
  21. Miranda B, Ferro JM, Canhão P, et al. Venous thromboembolic events after cerebral vein thrombosis. Stroke 2010; 41:1901.
  22. Dentali F, Poli D, Scoditti U, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10:1297.
  23. Benamer HT, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolyic therapy? J Neurol Neurosurg Psychiatry 2000; 69:427.
  24. Bousser MG. Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? Stroke 1999; 30:481.
  25. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30:484.
  26. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352:1791.
  27. Coutinho JM, Stam J. How to treat cerebral venous and sinus thrombosis. J Thromb Haemost 2010; 8:877.
  28. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338:597.
  29. Stam J, De Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev 2002; :CD002005.
  30. Maiti B, Chakrabarti I. Study on cerebral venous thrombosis with special reference to efficacy of heparin. J Neurol Sci 1997; 150:s147.
  31. Nagaraja D, Rao BSS, Taly AB, Subhash MN. Randomized controlled trial of heparin in puerperal cerebral venous/sinus thrombosis. Nimhans Journal 1995; 13:111.
  32. Misra UK, Kalita J, Chandra S, et al. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol 2012; 19:1030.
  33. Coutinho JM, Ferro JM, Canhão P, et al. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 2010; 41:2575.
  34. Einhäupl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17:1229.
  35. Ferro JM, Correia M, Pontes C, et al. Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998. Cerebrovasc Dis 2001; 11:177.
  36. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis--a review of 38 cases. Stroke 1985; 16:199.
  37. Brucker AB, Vollert-Rogenhofer H, Wagner M, et al. Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis 1998; 8:331.
  38. Wingerchuk DM, Wijdicks EF, Fulgham JR. Cerebral venous thrombosis complicated by hemorrhagic infarction: factors affecting the initiation and safety of anticoagulation. Cerebrovasc Dis 1998; 8:25.
  39. deVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol 1998; 55:1533.
  40. deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345:417.
  41. Johnson MC, Parkerson N, Ward S, de Alarcon PA. Pediatric sinovenous thrombosis. J Pediatr Hematol Oncol 2003; 25:312.
  42. Sébire G, Tabarki B, Saunders DE, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005; 128:477.
  43. Schobess R, Düring C, Bidlingmaier C, et al. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica 2006; 91:1701.
  44. Golomb MR. The risk of recurrent venous thromboembolism after paediatric cerebral sinovenous thrombosis. Lancet Neurol 2007; 6:573.
  45. Moharir MD, Shroff M, Stephens D, et al. Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study. Ann Neurol 2010; 67:590.
  46. Bagley LJ, Hurst RW, Galetta S, et al. Use of a microsnare to aid direct thrombolytic therapy of dural sinus thrombosis. AJR Am J Roentgenol 1998; 170:784.
  47. Scarrow AM, Williams RL, Jungreis CA, et al. Removal of a thrombus from the sigmoid and transverse sinuses with a rheolytic thrombectomy catheter. AJNR Am J Neuroradiol 1999; 20:1467.
  48. Mortimer AM, Bradley MD, O'Leary S, Renowden SA. Endovascular treatment of children with cerebral venous sinus thrombosis: a case series. Pediatr Neurol 2013; 49:305.
  49. Horowitz M, Purdy P, Unwin H, et al. Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995; 38:58.
  50. Frey JL, Muro GJ, McDougall CG, et al. Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin. Stroke 1999; 30:489.
  51. Kim SY, Suh JH. Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase. AJNR Am J Neuroradiol 1997; 18:639.
  52. Wasay M, Bakshi R, Kojan S, et al. Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis. Stroke 2001; 32:2310.
  53. Stam J, Majoie CB, van Delden OM, et al. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke 2008; 39:1487.
  54. Canhão P, Falcão F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis 2003; 15:159.
  55. Siddiqui FM, Dandapat S, Banerjee C, et al. Mechanical thrombectomy in cerebral venous thrombosis: systematic review of 185 cases. Stroke 2015; 46:1263.
  56. Unpublished data, International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).
  57. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.
  58. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160.
  59. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:1158.
  60. Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.
  61. Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.
  62. Canhão P, Cortesão A, Cabral M, et al. Are steroids useful to treat cerebral venous thrombosis? Stroke 2008; 39:105.
  63. Ferro JM, Crassard I, Coutinho JM, et al. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke 2011; 42:2825.
  64. Acheson JF. Optic nerve disorders: role of canal and nerve sheath decompression surgery. Eye (Lond) 2004; 18:1169.
  65. Ferro JM, Canhão P, Bousser MG, et al. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008; 39:1152.
  66. Price M, Günther A, Kwan JS. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database Syst Rev 2014; 8:CD005501.
  67. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992; 10:87.
  68. Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 2004; 21:639.
  69. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.
  70. Ferro JM, Correia M, Rosas MJ, et al. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003; 15:78.
  71. Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60:1418.
  72. Higgins JN, Gillard JH, Owler BK, et al. MR venography in idiopathic intracranial hypertension: unappreciated and misunderstood. J Neurol Neurosurg Psychiatry 2004; 75:621.
  73. Higgins JN, Owler BK, Cousins C, Pickard JD. Venous sinus stenting for refractory benign intracranial hypertension. Lancet 2002; 359:228.
  74. Owler BK, Parker G, Halmagyi GM, et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98:1045.
  75. Tsumoto T, Miyamoto T, Shimizu M, et al. Restenosis of the sigmoid sinus after stenting for treatment of intracranial venous hypertension: case report. Neuroradiology 2003; 45:911.
  76. Ferro JM, Canhão P, Bousser MG, et al. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke 2005; 36:1927.
  77. Purvin VA, Trobe JD, Kosmorsky G. Neuro-ophthalmic features of cerebral venous obstruction. Arch Neurol 1995; 52:880.
  78. Madureira S, Canhão P, Ferro JM. Cognitive and behavioural outcome of patients with cerebral venous thrombosis. Cerebrovasc Dis 2001; 11 Suppl 4:108.
  79. de Bruijn SF, Budde M, Teunisse S, et al. Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis. Neurology 2000; 54:1687.
  80. Lamy C, Hamon JB, Coste J, Mas JL. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. French Study Group on Stroke in Pregnancy. Neurology 2000; 55:269.
  81. Srinivasan K. Cerebral venous and arterial thrombosis in pregnancy and puerperium. A study of 135 patients. Angiology 1983; 34:731.
  82. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:1545.
  83. Jilma B, Kamath S, Lip GY. Antithrombotic therapy in special circumstances. I--pregnancy and cancer. BMJ 2003; 326:37.